![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-term Safety Profile of Tenofovir Alafenamide
in Chronic Hepatitis B Patients: Final 8-Year Results of 2 Phase 3 Studies
|
|
|
EASL 2023 June 21-24 Vienna
EASL 2023 - Long-term Efficacy of Tenofovir Alafenamide in HBeAg-positive and HBeAg-negative Chronic Hepatitis B Patients Treated for up to 8 Years in 2 Phase 3 Studies - (06/26/22)
Young-Suk Lim1, Henry Lik Yuen Chan2, Kosh Agarwal3, Patrick Marcellin4, Maurizia R Brunetto5, Wan-Long Chuang6, Harry LA Janssen7,8, Scott K Fung9, Namiki Izumi10, Maciej S Jablkowski11, Frida Abramov12, Hongyuan Wang12,
Leland J Yee12, John F Flaherty12, Calvin Pan13, Dr Shalimar14, Wai-Kay Seto15, Edward J Gane16, Maria Buti17,18
![0703231](../images/070323/070323-4/0703231.gif)
![0703232](../images/070323/070323-4/0703232.gif)
![0703233](../images/070323/070323-4/0703233.gif)
![0703234](../images/070323/070323-4/0703234.gif)
![0703235](../images/070323/070323-4/0703235.gif)
![0703236](../images/070323/070323-4/0703236.gif)
![0703237](../images/070323/070323-4/0703237.gif)
![0703238](../images/070323/070323-4/0703238.gif)
The Aging Kidney: physiological changes, Weinstein JR, Adv Chronic Kidney Dis., 2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901622/
![0703239](../images/070323/070323-4/0703239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|